Drug antagonising the Receptor for Advanced Glycation Endproducts (RAGE) pathway is shown to provide clinical benefit in maintenance of cognitive function in Alzheimer’s disease patients. The drug acts, in part, by restoring the normal balance of amyloid protein transport into and out of the brain.
(Note on tox/clinical trial halting "...although individuals enrolled
in the trial at the highest tested dose experienced signs of toxicity,
those effects were reversible, and the lower dose resulted in the
benefits and lack of adverse events reported here...")
http://www.drugdiscoveryonline.com/doc.mvc/novel-oral-drug-disease-modification-alzheimer-s-patients-0001?sectionCode=News&templateCode=EnhancedStandard&user=1935203&source=nl%3A35474
(Note on tox/clinical trial halting "...although individuals enrolled
in the trial at the highest tested dose experienced signs of toxicity,
those effects were reversible, and the lower dose resulted in the
benefits and lack of adverse events reported here...")
http://www.drugdiscoveryonline.com/doc.mvc/novel-oral-drug-disease-modification-alzheimer-s-patients-0001?sectionCode=News&templateCode=EnhancedStandard&user=1935203&source=nl%3A35474
Comments